farletuzumab
mAbexperimental
Farletuzumab (MORAb-003) is a humanized monoclonal antibody of IgG1/κ which is being investigated for the treatment of ovarian cancer. — Wikipedia
Clinical trial activity
10 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00428766)
Timeline
Indications
Mechanism of action
- Folate receptor alphaINHIBITOR
FOLR1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFarletuzumab ↗
- ChEMBLCHEMBL1743016 ↗
Also known as
- fareletuzumab
- farletuzumab
- farletuzumab
- farletuzumab
- farletuzumab
- m3
- m3
- morab-003
- morab-003
- morab-003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02289950 | Phase 2 | Mar 1, 2015 | Eisai, Morphotek |
| NCT01218516 | Phase 2 | Apr 1, 2011 | Morphotek |
| NCT01203618 | Phase 2 | Feb 1, 2011 | Emory University, Morphotek |
| NCT01049061 | Phase 1 | Jan 1, 2010 | Eisai |
| NCT01018563 | Phase 2 | Nov 1, 2009 | Morphotek |
| NCT01004380 | Phase 1 | Nov 1, 2009 | Morphotek |
| NCT00849667 | Phase 3 | Apr 1, 2009 | Morphotek |
| NCT00738699 | Phase 2 | Sep 1, 2008 | Morphotek |
| NCT00318370 | Phase 2 | May 1, 2006 | Morphotek |
| NCT00428766 | Phase 1 | Jun 1, 2005 | Cornell University, Morphotek |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Morphotek | For profit | 9 | 9 | 3 | 2005 |
| Eisai | For profit | 2 | 1 | 2 | 2010 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1